BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32437909)

  • 21. AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance.
    Jia Y; Guo J; Zhao Y; Zhang Z; Shi L; Fang Y; Wu D; Wu L; Chang C
    Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(4):492-500. PubMed ID: 33709099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages.
    Sada E; Abe Y; Ohba R; Tachikawa Y; Nagasawa E; Shiratsuchi M; Takayanagi R
    Eur J Haematol; 2010 Dec; 85(6):538-48. PubMed ID: 20887388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
    Piya S; Kornblau SM; Ruvolo VR; Mu H; Ruvolo PP; McQueen T; Davis RE; Hail N; Kantarjian H; Andreeff M; Borthakur G
    Blood; 2016 Sep; 128(9):1260-9. PubMed ID: 27268264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
    Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
    Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
    Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
    Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
    Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
    Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.
    Silva G; Cardoso BA; Belo H; Almeida AM
    PLoS One; 2013; 8(1):e53766. PubMed ID: 23320102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
    He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
    J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.